Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis

This clinical trial compares the efficacy of continuous vs intermittent infusion of a β-lactam antibiotic (piperacillin-tazobactam or meropenem) in decreasing all-cause mortality at 90 days in critically ill patients with sepsis.